Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity

Fotini Papachristou1, Ekaterini Chatzaki, Athanasios Petrou

  • 1Cell Cultures Unit, Laboratory of Experimental Surgery and Surgical Research, Faculty of Medicine, Democritus University of Thrace, Dragana, Alexandroupolis, Greece. atsarouc@med.duth.gr.

Chinese Medicine
|May 7, 2013
PubMed
Abstract

Insights

Apigenin (AP) shows anticancer potential by inducing genotoxicity and altering apoptotic protein levels in HepG2 cells. This natural compound affects cell survival and DNA damage response pathways.

Area of Science:

  • Pharmacology
  • Cell Biology
  • Genetics

Background:

  • Apigenin (AP), a natural compound from medicinal herbs, has demonstrated in vitro and in vivo anticancer properties.
  • This study investigates AP's effects on HepG2 cells, focusing on genotoxicity, cytostasis, and apoptosis.

Purpose of the Study:

  • To evaluate the genotoxic, cytostatic, and cytotoxic effects of Apigenin (AP) in HepG2 cells.
  • To analyze time-dependent changes in anti- and pro-apoptotic protein levels following AP treatment.

Main Methods:

  • Genotoxicity assessed via sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs).
  • Cytotoxicity and cytostaticity evaluated using MTT assays, proliferation rates, and mitotic indices.
  • Apoptosis induction and related protein expression (Bax, Bcl-2, sFas) determined by ELISA.

Main Results:

  • Apigenin decreased HepG2 cell survival in a dose- and time-dependent manner.
  • SCE rates and cell proliferation were significantly affected by AP in a dose-dependent way.
  • Apigenin treatment altered levels of apoptosis-related proteins, including reduced Bcl-2 and increased Bax and soluble Fas, influencing the Bax/Bcl-2 ratio.

Conclusions:

  • Apigenin exhibits dose-dependent genotoxic effects in HepG2 cells.
  • AP modulates the expression of sFas, Bcl-2, and Bax, influencing both cell survival and cell death pathways.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cellular Injury V: Apoptosis and Autophagy01:22

Cellular Injury V: Apoptosis and Autophagy

Cells respond to damage and stress through highly coordinated processes that decide whether they survive or undergo controlled self-destruction. Two major pathways involved in this regulation are apoptosis, a type of programmed cell death, and autophagy, a survival mechanism that helps cells adapt to adverse conditions.ApoptosisApoptosis removes aged or injured cells to maintain tissue balance. During this process, the cell shrinks, chromatin condenses and fragments, and membrane-bound...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...